Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IND128
- Development stage
- Preclinical
- Lead developer
- Vegen Therapeutics
- Modality
- Small Molecules
01
Overview
IND128 is a targeted small molecule inhibitor of the KRAS G12C mutant protein, currently under development by VeGen. The drug is designed to treat solid tumors harboring the G12C mutation, which is a common oncogenic driver in several malignancies. IND128 is specifically being advanced for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC). It is currently in the IND-enabling stage of development, aiming to transition into clinical trials to evaluate its safety and efficacy in patients with these specific genetic alterations. By selectively binding to the mutant KRAS protein, IND128 blocks downstream signaling pathways that are critical for tumor cell proliferation and survival.
02
Targets
Beyond the preview
Go deeper on IND128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IND128.